Arecor Therapeutics PLC (AREC) - Total Liabilities

Latest as of December 2025: GBX1.65 Million GBX ≈ $200.39 USD

Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has total liabilities worth GBX1.65 Million GBX (≈ $200.39 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Arecor Therapeutics PLC to evaluate the company's liquid asset resilience ratio.

Arecor Therapeutics PLC - Total Liabilities Trend (2017–2025)

This chart illustrates how Arecor Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AREC current and non-current assets.

Arecor Therapeutics PLC Competitors by Total Liabilities

The table below lists competitors of Arecor Therapeutics PLC ranked by their total liabilities.

Company	Country	Total Liabilities
Hill Street Beverage Company Inc V:HILL	Canada	CA$3.64 Million
Sleep Number Corp NASDAQ:SNBR	USA	$1.27 Billion
Dewata Freight International Tbk PT JK:DEAL	Indonesia	Rp207.97 Billion
AFFINOR GROWERS INC. F:1AF0	Germany	€1.83 Million
Kendrick Resources PLC LSE:KEN	UK	GBX1.27 Million
CABASSE S.A. EO -50 F:LB0	Germany	€10.20 Million
Chelverton UK Dividend Trust PLC LSE:SDV	UK	GBX173.00K
Anexo Group Plc LSE:ANX	UK	GBX115.42 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Arecor Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Arecor Therapeutics PLC to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.35	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Arecor Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Arecor Therapeutics PLC (2017–2025)

The table below shows the annual total liabilities of Arecor Therapeutics PLC from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	GBX1.65 Million ≈ $200.39	-51.17%
2024-12-31	GBX3.37 Million ≈ $410.40	-42.34%
2023-12-31	GBX5.85 Million ≈ $711.78	+35.73%
2022-12-31	GBX4.31 Million ≈ $524.40	+81.70%
2021-12-31	GBX2.37 Million ≈ $288.60	-32.42%
2020-12-31	GBX3.51 Million ≈ $427.07	+219.76%
2019-12-31	GBX1.10 Million ≈ $133.56	-11.12%
2019-05-31	GBX1.23 Million ≈ $150.26	-11.56%
2018-05-31	GBX1.40 Million ≈ $169.90	+13.33%
2017-05-31	GBX1.23 Million ≈ $149.92	--

About Arecor Therapeutics PLC

LSE:AREC UK Biotechnology

Market Cap

$401.97K

GBX3.30 Billion GBX

Market Cap Rank

#31139 Global

#956 in UK

Share Price

GBX87.50

Change (1 day)

+0.00%

52-Week Range

GBX57.50 - GBX92.50

All Time High

GBX450.00